Xantos Biomedicine AG Receives Funding From Sixth EU Framework Program For Angiotargeting Project
In addition to the discovery and validation of new targets and inhibitors of blood vessel formation and invasion, the project will involve the implementation of clinical trials. Xantos specific role in the project will be to develop novel cDNA libraries from the vascular transcriptome (the set of all cellular messenger RNA transcripts that are present in the blood vessels) and novel assays for the discovery of angiogenesis modulators. The whole project is supported with EUR 6 million from the EU.
The project integrates the core skills and competencies of an additional thirteen research centers, including two companies, working within the field of angiogenesis. These include: University of Bergen, European Institute of Oncology Milano, University of Uppsala, Netherlands Cancer Institute, University of Maastricht, University of Oxford, VU Medical Center, University of Oulu, Institute of Experimental Medicine, Academy of Sciences Czech Republic, NorLux, the Karolinska Institute and Pharmatarget.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.